Abnormal Factor Viii Activity C4476889
Reduced Factor VIII activity prevents normal blood clotting, characteristic of Hemophilia A. This inherited bleeding disorder mainly affects males and is managed with factor replacement therapy and preventive care.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Intracranial bleeding
Life-threatening bleeding inside the skull causes sudden severe headache, vision changes, weakness, confusion, or loss of consciousness.
EMERGENCY: Call emergency services immediately if experiencing sudden severe headache, vision changes, weakness, confusion, or loss of consciousness.
Internal abdominal bleeding
Bleeding inside the abdomen causes severe abdominal pain, swelling, dizziness, and signs of shock.
EMERGENCY: Seek immediate emergency care for sudden severe abdominal pain, fainting, or signs of shock.
Prolonged bleeding
(hematologic)Bleeding continues longer than normal after a cut, injury, or surgical procedure due to impaired clot formation.
Frequency: 90-95% of patients
Joint swelling and pain
(musculoskeletal)Bleeding into joints causes swelling, warmth, stiffness, and severe pain, commonly affecting knees, elbows, and ankles.
Frequency: 70-80% of patients
Easy bruising
(dermatologic)Bruises appear frequently and may be larger than expected even with minor bumps or trauma.
Frequency: 80-90% of patients
Muscle hematoma
(musculoskeletal)Bleeding into muscles causes a painful, swollen lump under the skin, often in the thighs, calves, or arms.
Frequency: 40-50% of patients
Nosebleeds
(respiratory)Recurrent or prolonged nosebleeds that are difficult to stop, often occurring spontaneously or with minor irritation.
Frequency: 30-40% of patients
Gum bleeding
(gastrointestinal)Gums bleed easily during brushing, eating, or even spontaneously, indicating poor clot formation in oral tissues.
Frequency: 35-45% of patients
Blood in urine
(genitourinary)Hematuria appears as pink, red, or brown urine, indicating bleeding in the urinary tract.
Frequency: 10-20% of patients
Unexplained fatigue
(constitutional)Persistent tiredness and weakness due to chronic blood loss or anemia from ongoing minor bleeding episodes.
Frequency: 40-50% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Factor VIII Replacement Therapy
Standard treatment involving regular intravenous infusions of recombinant or plasma-derived factor VIII to prevent or treat bleeding. May be given prophylactically to prevent spontaneous bleeding or on-demand for acute episodes.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Emicizumab Prophylaxis
Monoclonal antibody therapy providing subcutaneous prophylaxis by bridging factor IXa and factor X to restore missing factor VIII function. Offers fewer infusions than traditional factor replacement.
Additional treatment options
Desmopressin (DDAVP) Trial
Synthetic hormone that stimulates release of stored factor VIII and von Willebrand factor from endothelial cells. Used primarily for mild hemophilia A to raise factor levels temporarily.
medicationActivity Modification and Safety Planning
Personalized activity guidance to prevent injury while maintaining physical fitness. Includes recommendations for appropriate sports, protective equipment, and environmental modifications to reduce bleeding risk.
lifestylePsychosocial Support Services
Counseling and support services addressing anxiety, depression, and adjustment challenges associated with chronic bleeding disorders. Includes family counseling, peer support groups, and coping skills training.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Abnormal Factor Viii Activity C4476889?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
World Federation of Hemophilia. Guidelines for the Management of Hemophilia. 3rd Edition. WFH; 2020.
National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Recommendations on Factor VIII Inhibitor Testing. NHF; 2021.
Fischer K, Kogler M, Ljung R, et al. Hemophilia treatment in children: recommendations from the European Haemophilia Network. Blood Transfusion. 2020;18(5):337-350.
Centers for Disease Control and Prevention. Hemophilia: Facts and Statistics. CDC; 2022.
Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab Prophylaxis in Patients with Hemophilia A with Inhibitors. New England Journal of Medicine. 2018;377(9):819-828.
Iorio A, Oliovecchio E, Morrison AE, et al. Inhibitor development in hemophilia A patients treated with emicizumab: a systematic review. Journal of Thrombosis and Haemostasis. 2021;19(8):1893-1906.
American Society of Hematology. ASH Clinical Practice Guidelines: Hemophilia A and B. ASH; 2020.
Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB. Postgraduate Haematology. 7th Edition. Wiley-Blackwell; 2021.
International Society on Thrombosis and Haemostasis. ISTH Guideline on Diagnosis and Management of Hemophilia A and B. ISTH; 2022.
Castaman G, Linari S. Diagnosis and treatment of acquired hemophilia A. Haematologica. 2019;104(9):1721-1729.
Medication Comparisons
Compare medications used to treat Abnormal Factor Viii Activity C4476889. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy